AbbVie Inc.
ABBVPharmaceuticals
$294.89+1.41%As of Oct 30vs prior close
- Market cap
- $521.1B
- P/E (TTM)
- 83.1×
- P/E (FY1)
- 21.1×
- From 52W high
- 0.00%
- EPS (LTM)
- $3.54
- Revenue (LTM)
- $64.4B
- Net margin
- 9.80%
- Dividend yield
- 2.35%
Nomior Score
68
Steady ProfileTop 12% of the scored universe
Growth50
Quality71
Value48
Momentum79
Resilience59
Growth
+10.14%revenue a year over 9 fiscal years
FY16 $25.6BLTM $64.4B
Connections
Revenue to profitQ2 FY26
21% of revenue became net profit, up 15 pts on a year.
Latest resultsthird quarter ended September 30, 2026
- Revenue
- $17.404 billion
- Diluted EPS
- $2.37
- Adjusted EPS
- $3.82
Net revenues grew in the quarter, led by strong growth in immunology and neuroscience, while Humira declined sharply and aesthetics and oncology were broadly flat or down. Diluted and adjusted earnings per share were reported for the quarter, with acquired IPR&D and milestones expense weighing on results. The company raised its full-year adjusted EPS guidance and completed the Apogee Therapeutics acquisition.
Who owns it
6funds, 7 tracked portfolios